Regenxbio Inc
RGNX10.330USD
+0.070+0.68%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
522.89MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Regenxbio Inc Unternehmen
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Regenxbio Inc Informationen
BörsenkürzelRGNX
Name des UnternehmensRegenxbio Inc
IPO-datumSep 17, 2015
CEOSimpson (Curran M)
Anzahl der mitarbeiter353
WertpapierartOrdinary Share
GeschäftsjahresendeSep 17
Addresse9804 Medical Center Drive
StadtROCKVILLE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl20850
Telefon12405528181
Websitehttps://regenxbio.com/
BörsenkürzelRGNX
IPO-datumSep 17, 2015
CEOSimpson (Curran M)
Führungskräfte von Regenxbio Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+73749.00%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
121.60K
+105494.00%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+64609.00%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-71824.00%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+7768.00%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+7768.00%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+7768.00%
Mr. Kenneth T. (Ken) Mills
Mr. Kenneth T. (Ken) Mills
Chairman of the Board
Chairman of the Board
--
--
Dr. A. N. (Jerry) Karabelas, Ph.D.
Dr. A. N. (Jerry) Karabelas, Ph.D.
Independent Director
Independent Director
--
--
Mr. Allan M. Fox, J.D.
Mr. Allan M. Fox, J.D.
Director
Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+73749.00%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
121.60K
+105494.00%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+64609.00%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-71824.00%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+7768.00%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+7768.00%
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Wed, Jan 14
Aktualisiert: Wed, Jan 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Redmile Group, LLC
9.27%
BlackRock Institutional Trust Company, N.A.
8.21%
The Vanguard Group, Inc.
6.67%
Fox (Allan Mark)
5.73%
JP Morgan Asset Management
5.16%
Andere
64.96%
Aktionäre
Aktionäre
Anteil
Redmile Group, LLC
9.27%
BlackRock Institutional Trust Company, N.A.
8.21%
The Vanguard Group, Inc.
6.67%
Fox (Allan Mark)
5.73%
JP Morgan Asset Management
5.16%
Andere
64.96%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
33.70%
Investment Advisor
31.87%
Research Firm
9.14%
Hedge Fund
8.86%
Individual Investor
8.29%
Private Equity
0.50%
Family Office
0.31%
Bank and Trust
0.25%
Pension Fund
0.11%
Andere
6.96%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
409
42.96M
84.86%
-6.45M
2025Q3
403
44.05M
87.32%
-5.71M
2025Q2
421
48.19M
95.62%
-3.63M
2025Q1
446
48.46M
96.35%
-3.90M
2024Q4
444
48.16M
97.22%
-4.82M
2024Q3
444
49.64M
100.43%
-4.45M
2024Q2
437
49.30M
99.98%
-3.20M
2024Q1
451
48.23M
99.21%
+414.63K
2023Q4
436
43.62M
98.84%
-7.14M
2023Q3
439
43.73M
99.56%
-6.26M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Redmile Group, LLC
4.69M
9.27%
-82.33K
-1.72%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.16M
8.21%
-109.09K
-2.56%
Sep 30, 2025
The Vanguard Group, Inc.
3.34M
6.59%
-83.09K
-2.43%
Sep 30, 2025
Fox (Allan Mark)
2.90M
5.73%
+7.77K
+0.27%
May 30, 2025
JP Morgan Asset Management
2.61M
5.16%
-375.24K
-12.57%
Sep 30, 2025
State Street Investment Management (US)
1.98M
3.92%
+141.23K
+7.66%
Sep 30, 2025
Goldman Sachs & Company, Inc.
1.62M
3.2%
+15.37K
+0.96%
Sep 30, 2025
BlackRock Financial Management, Inc.
1.50M
2.97%
-226.30K
-13.07%
Sep 30, 2025
Morgan Stanley & Co. LLC
1.45M
2.85%
+700.19K
+94.00%
Sep 30, 2025
AQR Capital Management, LLC
1.29M
2.55%
+359.46K
+38.64%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
WisdomTree BioRevolution Fund
2.25%
iShares Neuroscience and Healthcare ETF
1.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Global X Genomics & Biotechnology ETF
0.65%
JPMorgan Fundamental Data Science Small Core ETF
0.45%
ALPS Medical Breakthroughs ETF
0.27%
State Street SPDR S&P Biotech ETF
0.24%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
Fidelity Enhanced Small Cap ETF
0.12%
ProShares Ultra Nasdaq Biotechnology
0.08%
Mehr Anzeigen
WisdomTree BioRevolution Fund
Anteil2.25%
iShares Neuroscience and Healthcare ETF
Anteil1.02%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.85%
Global X Genomics & Biotechnology ETF
Anteil0.65%
JPMorgan Fundamental Data Science Small Core ETF
Anteil0.45%
ALPS Medical Breakthroughs ETF
Anteil0.27%
State Street SPDR S&P Biotech ETF
Anteil0.24%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.13%
Fidelity Enhanced Small Cap ETF
Anteil0.12%
ProShares Ultra Nasdaq Biotechnology
Anteil0.08%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
